Clinical Trials of Adult T-Cell Leukaemia/Lymphoma Treatment

  • Marçais A
  • Suarez F
  • Sibon D
  • et al.
N/ACitations
Citations of this article
27Readers
Mendeley users who have this article in their library.

Abstract

Adult T-cell leukaemia/lymphoma (ATLL) is an aggressive malignancy of mature activated T cells caused by human T-cell lymphotropic virus type I (HTLV-1). Prognosis is severe because of intrinsic chemoresistance and severe immuosuppression. Four different subtypes are described with different outcomes, and treatment strategies vary according to the different clinical courses. Japanese trials show that combinations of chemotherapy can increase the response rates especially in the lymphoma subtype. However, patients have a high rate of relapse and the outcome remains extremely poor. Recently, a worldwide meta-analysis demonstrated that the combination of Zidovudine and Interferon-alpha (IFN) is effective in the leukemic subtypes (smoldering, chronic, and acute) and influences favorably the course of the disease. In order to prevent relapse, clinical trials testing new drugs such as monoclonal antibodies or combinations such as arsenic/IFN are needed. Finally, allogeneic stem cell transplantation is a feasible option but bears a very high rate of complications.

Cite

CITATION STYLE

APA

Marçais, A., Suarez, F., Sibon, D., Bazarbachi, A., & Hermine, O. (2012). Clinical Trials of Adult T-Cell Leukaemia/Lymphoma Treatment. Leukemia Research and Treatment, 2012, 1–8. https://doi.org/10.1155/2012/932175

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free